Guinea-Bissau vs Netherlands: Access to anti-retroviral drugs, female
Guinea-Bissau
89.0%
in 2024
Netherlands
89.0%
in 2023
Guinea-Bissau rank
35th
Netherlands rank
35th
Access to anti-retroviral drugs, female over time
- Guinea-Bissau
- Netherlands
How they compare
Guinea-Bissau currently reports 89.0% against 89.0% in Netherlands, a difference of 0.0%.
Across all 24 years both countries report, Netherlands has been ahead every year.
Guinea-Bissau ranks 35th and Netherlands ranks 35th of 141 countries.
Netherlands has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Guinea-Bissau | Netherlands | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.7% | 62.9% | 61.2% | Netherlands |
| 2010s | 32.2% | 77.7% | 45.5% | Netherlands |
| 2020s | 68.8% | 86.8% | 18.0% | Netherlands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Guinea-Bissau or Netherlands?
- Guinea-Bissau, at 89.0% against 89.0% in Netherlands as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Guinea-Bissau and Netherlands?
- 0.0%, with Guinea-Bissau ahead.
- How many years of comparable data are there for Guinea-Bissau and Netherlands?
- 24 years are reported by both, from 2000 to 2023.
- How do Guinea-Bissau and Netherlands rank globally for access to anti-retroviral drugs, female?
- Guinea-Bissau ranks 35th and Netherlands ranks 35th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.